KR20200037851A - 장내 항생제 내성 박테리아를 탈콜론화하기 위한 조성물 및 방법 - Google Patents

장내 항생제 내성 박테리아를 탈콜론화하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20200037851A
KR20200037851A KR1020207006802A KR20207006802A KR20200037851A KR 20200037851 A KR20200037851 A KR 20200037851A KR 1020207006802 A KR1020207006802 A KR 1020207006802A KR 20207006802 A KR20207006802 A KR 20207006802A KR 20200037851 A KR20200037851 A KR 20200037851A
Authority
KR
South Korea
Prior art keywords
bacterial
pharmaceutical composition
rrna sequence
bacterial strains
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207006802A
Other languages
English (en)
Korean (ko)
Inventor
마리나 산티아고
케빈 롤로프스
Original Assignee
핀치 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 핀치 테라퓨틱스, 인코포레이티드 filed Critical 핀치 테라퓨틱스, 인코포레이티드
Publication of KR20200037851A publication Critical patent/KR20200037851A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C12R1/01—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020207006802A 2017-08-07 2018-08-07 장내 항생제 내성 박테리아를 탈콜론화하기 위한 조성물 및 방법 Ceased KR20200037851A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762542033P 2017-08-07 2017-08-07
US62/542,033 2017-08-07
PCT/US2018/045592 WO2019032572A1 (en) 2017-08-07 2018-08-07 COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES

Publications (1)

Publication Number Publication Date
KR20200037851A true KR20200037851A (ko) 2020-04-09

Family

ID=65272652

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207006802A Ceased KR20200037851A (ko) 2017-08-07 2018-08-07 장내 항생제 내성 박테리아를 탈콜론화하기 위한 조성물 및 방법

Country Status (8)

Country Link
US (2) US20200093870A1 (https=)
EP (1) EP3665181A4 (https=)
JP (1) JP2020530493A (https=)
KR (1) KR20200037851A (https=)
CN (1) CN111328331A (https=)
AU (1) AU2018313765A1 (https=)
CA (1) CA3072029A1 (https=)
WO (1) WO2019032572A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240072307A (ko) * 2022-11-09 2024-05-24 주식회사 굿바이옴텍 베타-락탐계 항생제 내성 유전자 ｂｌａＣＴＸ－Ｍ－２２９ 및 퀴놀론계 항생제 내성 유전자 ｑｎｒＳ를 갖는 신규한 다제내성 대장균 균주 및 이의 용도

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
UY37939A (es) * 2017-10-18 2019-04-30 Ascus Biosciences Inc Aumento de la producción de aves de corral mediante la administración de un bioensamblaje sintético de microbios o cepas purificadas de los mismos
EP3773645A4 (en) 2018-04-10 2021-11-24 Siolta Therapeutics, Inc. MICROBIAL CONSORTIA
BR112021012118A2 (pt) * 2018-12-19 2021-09-08 Healthy Cow Corporation Composição probiótica em forma de gel, produto probiótico pronto para uso, kit, sistema, e, métodos para introduzir uma ou mais cepas de bactérias à vagina de um animal não humano, para tratar uma infecção uterina ou diminuir o risco de contrair uma infecção uterina em um animal não humano e para promover o estabelecimento ou manutenção de um microbioma vaginal saudável em um animal não humano
PH12021553137A1 (en) 2019-07-19 2022-07-25 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
US20220339212A1 (en) * 2019-08-28 2022-10-27 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
JP2022548785A (ja) 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド 炎症性疾患及び免疫疾患の治療のための組成物及び方法
CN120732903A (zh) 2019-10-07 2025-10-03 谢尔塔治疗公司 治疗性药物组合物
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN115279382A (zh) * 2019-10-18 2022-11-01 芬奇治疗控股有限责任公司 用于向受试者递送细菌代谢物的组合物和方法
EP3838281A1 (en) * 2019-12-20 2021-06-23 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021231804A2 (en) * 2020-05-13 2021-11-18 President And Fellows Of Harvard College Methods and compositions for suppressing inflammation induced by gut microbes
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
KR20230088680A (ko) 2020-08-14 2023-06-20 프롤랙타 바이오사이언스, 인코포레이티드 박테리아 요법에 사용하기 위한 인간 모유 올리고당 조성물
WO2022050082A1 (ja) * 2020-09-01 2022-03-10 国立大学法人東北大学 乳汁中のＩｇＡ抗体含有量の増加剤
CA3202362A1 (en) * 2020-09-30 2022-04-07 National Cancer Center Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium
WO2022115646A1 (en) * 2020-11-25 2022-06-02 Seres Therapeutics, Inc. Designed bacterial compositions for treating graft-versus-host-disease
US20230149483A1 (en) * 2021-11-12 2023-05-18 Iowa State University Research Foundation, Inc. Short-chain fatty acid use to mitigate antimicrobial resistance and virulence gene transfer in the gut
WO2023100989A1 (ja) * 2021-12-02 2023-06-08 国立大学法人東北大学 下痢治療剤および牛の下痢治療方法
CN116747227B (zh) * 2023-08-12 2025-07-25 杭州市第一人民医院 泊马度胺在制备抗细菌感染药物中的应用
WO2025093780A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. The concept of drugs made with the gut microbiota and its components and the method of their administration to obtain effective therapeutic effects
WO2025093778A1 (en) 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727061B2 (en) * 1997-02-20 2004-04-27 Cabtec, Inc. Methods for identifying species or Shigella and E. coli using operon sequence analysis
JP2003516151A (ja) * 1999-11-29 2003-05-13 エイブイアイ バイオファーマ， インコーポレイテッド 細菌１６Ｓおよび２３ＳｒＲＮＡに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用
US9968638B2 (en) * 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
ES2993669T3 (en) * 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US8921335B2 (en) * 2012-01-31 2014-12-30 The Regents Of The University Of California Oral delivery of nucleic acid-based gene interfering agents by Salmonella
WO2014145958A2 (en) * 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
KR102099503B1 (ko) * 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
JP2020530494A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240072307A (ko) * 2022-11-09 2024-05-24 주식회사 굿바이옴텍 베타-락탐계 항생제 내성 유전자 ｂｌａＣＴＸ－Ｍ－２２９ 및 퀴놀론계 항생제 내성 유전자 ｑｎｒＳ를 갖는 신규한 다제내성 대장균 균주 및 이의 용도

Also Published As

Publication number Publication date
AU2018313765A1 (en) 2020-02-27
EP3665181A1 (en) 2020-06-17
EP3665181A4 (en) 2021-06-09
US20240307460A1 (en) 2024-09-19
CA3072029A1 (en) 2019-02-14
CN111328331A (zh) 2020-06-23
US20200093870A1 (en) 2020-03-26
JP2020530493A (ja) 2020-10-22
WO2019032572A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
KR20200037851A (ko) 장내 항생제 내성 박테리아를 탈콜론화하기 위한 조성물 및 방법
AU2021204574B2 (en) Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
AU2020202312B2 (en) Compositions and methods for inhibition of pathogenic bacterial growth
KR20200038506A (ko) 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
KR102426653B1 (ko) 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
KR102379658B1 (ko) 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
AU2018338647B2 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
CN112673092B (zh) 工程化的免疫刺激性细菌菌株及其用途
AU2014232370B2 (en) Network-based microbial compositions and methods
AU2017235661B2 (en) Oligonucleotide probes and uses thereof
AU2024202444A1 (en) Ammonia-oxidizing nitrosomonas eutropha strain D23
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
TW202237826A (zh) 基因編輯的自然殺手細胞
AU2019316556B2 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
KR20200064980A (ko) 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물
AU2014338859B2 (en) Phage therapy of Pseudomonas infections
CN111867608A (zh) 用于痤疮和生物膜的噬菌体治疗
RU2825990C1 (ru) Композиции и способы
AU2024201593B2 (en) A genetically modified Lactobacillus and uses thereof
RU2804664C2 (ru) Hpv-специфические связывающие молекулы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210720

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230703

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230906

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230703

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I